Athénaïs Boucly
YOU?
Author Swipe
View article: Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting
Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting Open
View article: Beyond the shunt: Divergent insights from hyperoxia testing and contrast echocardiography in adults with pulmonary hypertension
Beyond the shunt: Divergent insights from hyperoxia testing and contrast echocardiography in adults with pulmonary hypertension Open
Our objective was to evaluate the agreement between hyperoxia test (HT) and contrast transthoracic echocardiography (CE) for shunt detection in patients with pulmonary hypertension (PH) and unexplained hypoxemia. We retrospectively collect…
View article: Outcomes of Critically Ill Adult Patients With Acute Encephalitis
Outcomes of Critically Ill Adult Patients With Acute Encephalitis Open
Importance Functional outcomes and long-term recovery after severe encephalitis are not well characterized. Objective To determine the incidence of functional disability or death at 3 months and to describe recovery trajectories through 1 …
View article: Cardiopulmonary Hemodynamic Determinants of Long-Term Survival in Sickle Cell Disease: Insights from the ETENDARD Study
Cardiopulmonary Hemodynamic Determinants of Long-Term Survival in Sickle Cell Disease: Insights from the ETENDARD Study Open
Rationale: Pulmonary hypertension is a serious cardiopulmonary complication of sickle cell disease, but the prognostic impact of hemodynamic parameters remains poorly defined. Objectives: This study aimed to assess the clinic…
View article: Pulmonary arterial stiffness as the main correlate of effective arterial elastance in pre- and post-capillary pulmonary hypertension
Pulmonary arterial stiffness as the main correlate of effective arterial elastance in pre- and post-capillary pulmonary hypertension Open
In PH patients, EasPAP most closely correlated with the PA pulse pressure/SV ratio, the standard clinical estimate of total PA stiffness. This overlap among clinical indices of PA load warrants recognition, suggesting right vent…
View article: The activin pathway in chronic thromboembolic pulmonary hypertension: a potential biomarker for residual pulmonary hypertension after endarterectomy
The activin pathway in chronic thromboembolic pulmonary hypertension: a potential biomarker for residual pulmonary hypertension after endarterectomy Open
Background Chronic thromboembolic pulmonary hypertension (CTEPH) is characterised by persistent pulmonary vascular obstruction due to unresolved thromboembolic lesions and distal pulmonary vascular remodelling. Despite the recognised role …
View article: Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome
Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome Open
Background: Patients with pulmonary hypertension are classified according to clinical criteria to inform treatment decisions. Knowledge of the molecular drivers of pulmonary hypertension might better inform treatment choice. Obje…
View article: Diuretic adherence in patients with pre-capillary pulmonary hypertension: insights from the PHARE study
Diuretic adherence in patients with pre-capillary pulmonary hypertension: insights from the PHARE study Open
Background Supportive treatments, such as diuretics, play a critical role in managing pulmonary hypertension (PH). While low adherence to oral PH therapies worsens outcomes, the impact of diuretic adherence is less clear. This study aimed …
View article: ERS Congress 2024: highlights from the Pulmonary Vascular Diseases Assembly
ERS Congress 2024: highlights from the Pulmonary Vascular Diseases Assembly Open
This article highlights hot topics presented at the #ERSCongress 2024 on pulmonary embolism, right heart failure and personalised medicine for pulmonary hypertension https://bit.ly/3Yvb7VR.
View article: Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension
Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension Open
Proteomic analysis of circulating biomarkers reveals that sotatercept's impact extends beyond activins to influence BMP-9 and BMP-10, along with essential metabolic and inflammatory factors https://bit.ly/3Z5AZJ3
View article: Risk stratification and treatment goals in pulmonary arterial hypertension
Risk stratification and treatment goals in pulmonary arterial hypertension Open
Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Healt…
View article: Role of Exercise Hemodynamics in the Prediction of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers
Role of Exercise Hemodynamics in the Prediction of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers Open
The results of this study indicate that before development of PAH in BMPR2 mutation carriers, α is reduced markedly and may serve as a useful parameter in the setting of early disease detection. Given the low event rate, caution is warrant…
View article: Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension
Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension Open
Background Haemodynamic variables are prognostic factors in pulmonary arterial hypertension (PAH). However, right heart catheterisation (RHC) is not systematically recommended to assess the risk status during follow-up. This study aimed to…
View article: Pulmonary veno-occlusive disease: illustrative cases and literature review
Pulmonary veno-occlusive disease: illustrative cases and literature review Open
Pulmonary veno-occlusive disease (PVOD), also known as “pulmonary arterial hypertension (PAH) with overt features of venous/capillary involvement”, is a rare cause of PAH characterised by substantial small pulmonary vein and capillary invo…
View article: Outcomes and risk assessment in pulmonary veno-occlusive disease
Outcomes and risk assessment in pulmonary veno-occlusive disease Open
Introduction Pulmonary veno-occlusive disease (PVOD) is a rare and severe subtype of pulmonary arterial hypertension (PAH). Although European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines advise assessing PAH seve…
View article: ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly
ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly Open
Pulmonary vascular diseases such as pulmonary embolism and pulmonary hypertension are important and frequently under-recognised conditions. This article provides an overview of key highlights in pulmonary vascular diseases from the Europea…
View article: Real‐world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real‐world Evidence Working Group
Real‐world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real‐world Evidence Working Group Open
This manuscript on real‐world evidence (RWE) in pulmonary hypertension (PH) incorporates the broad experience of members of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative Real‐World Evidence Working Grou…
View article: Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension
Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension Open
Background: Activins are novel therapeutic targets in pulmonary arterial hypertension (PAH). We therefore studied whether key members of the activin pathway could be used as PAH biomarkers. Methods: Serum levels of activin A, activin B, α-…
View article: Functional respiratory complaints among COVID-19 survivors: a prospective cohort study
Functional respiratory complaints among COVID-19 survivors: a prospective cohort study Open
Background Dyspnoea is a common persistent symptom after COVID-19. Whether it is associated with functional respiratory disorders remains unclear. Methods We assessed the proportion and characteristics of patients with “functional respirat…
View article: In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicentre study
In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicentre study Open
Objective Pulmonary arterial hypertension (PAH) is a leading cause of death in MCTD. We aimed to describe PAH in well-characterized MCTD patients. Methods MCTD patients enrolled in the French Pulmonary Hypertension Registry with a PAH diag…
View article: Cytokines as prognostic biomarkers in pulmonary arterial hypertension
Cytokines as prognostic biomarkers in pulmonary arterial hypertension Open
Background Risk stratification and assessment of disease progression in patients with pulmonary arterial hypertension (PAH) are challenged by the lack of accurate disease-specific and prognostic biomarkers. To date, brain natriuretic pepti…
View article: To be or not to be… treated with initial combination therapy, that is the (PAH) question
To be or not to be… treated with initial combination therapy, that is the (PAH) question Open
International audience
View article: An emerging phenotype of pulmonary arterial hypertension patients carrying<i>SOX17</i>variants
An emerging phenotype of pulmonary arterial hypertension patients carrying<i>SOX17</i>variants Open
Background The phenotype of pulmonary arterial hypertension (PAH) patients carrying SOX17 pathogenic variants remains mostly unknown. Methods We report the genetic analysis findings, characteristics and outcomes of patients with heritable …
View article: COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study
COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study Open
Rationale: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with pulmonary endothelial dysfunction. There are limited data available on the outcomes of coronavirus disease (COVID-19) in patients w…
View article: Symptômes respiratoires et anomalies radiologiques dans le COVID long
Symptômes respiratoires et anomalies radiologiques dans le COVID long Open
View article: Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers
Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers Open
View article: Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome
Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome Open
Rationale The characteristics of patients with respiratory complaints and/or lung radiologic abnormalities after hospitalisation for coronavirus disease 2019 (COVID-19) are unknown. The objectives were to determine their characteristics an…
View article: Prognostic biomarkers and risk stratification in PAH
Prognostic biomarkers and risk stratification in PAH Open
L’hypertension artérielle pulmonaire (HTAP) est une maladie rare dont le mauvais pronostic a longtemps été considéré comme inéluctable. Une dizaine de traitements sont aujourd’hui disponibles pour prendre en charge cette pathologie. Le cho…
View article: External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry Open
Introduction Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim…
View article: Reply to Jin <i>et al.</i> and to Sun <i>et al.</i>
Reply to Jin <i>et al.</i> and to Sun <i>et al.</i> Open